This study looks at a medicine called efinopegdutide to see how it affects fat in the liver. The liver is an important organ that helps clean your blood and break down food. Efinopegdutide will be given either every two weeks or weekly for 28 weeks to see which way works better to reduce liver fat. The study will also check if the medicine is safe and if people can handle it well.

Inclusion: You can join if you have a stable body weight and a BMI over 25 (or 23 for Asian people). You must not have type 2 diabetes, or if you do, it should be controlled.

Exclusion: You cannot join if you have other liver diseases, history of pancreatitis, type 1 diabetes, or some serious health problems. You also cannot join if you had weight-loss surgery in the last 5 years or have issues with MRI scans.

• Study lasts 28 weeks.
• Participants will get medicine every week or every two weeks.
• Safety and liver fat levels will be monitored.